Stanford University


Showing 121-130 of 519 Results

  • Alan Schroeder

    Alan Schroeder

    Clinical Professor, Pediatrics

    BioDr. Schroeder is the associate chief for research in the division of pediatric hospital medicine at Lucile Packard Children’s Hospital Stanford, and a clinical professor in the division of hospital medicine and the division of critical care. His research interests focus on identifying areas where we can “safely do less” in healthcare, striving to ensure that children get the healthcare that they need while avoiding excessive tests and treatments that only cause harm. Dr. Schroeder is currently involved in multiple projects involving common conditions and interventions in pediatrics. He serves as the Stanford PI for PEDSNet and is an Associate Editor for the journal Hospital Pediatrics. At Stanford he co-leads the residency clinical research scholarly concentration and the faculty Clinical Research Peer Scholarship Community. Dr. Schroeder provides clinical care for children in the PICU and the pediatric ward.

  • John S. Schroeder, MD

    John S. Schroeder, MD

    Professor (Clinical) of Medicine (Cardiovascular), Emeritus

    Current Research and Scholarly Interests1. Clinical Pharmocology of Cardiovascular Drugs
    (a) Calcium Channel Blockers
    (b) Agents for Heart Failure
    (c) Anti-atherosclerotic Effects of Cardiovascular Drugs, e.g. Calcium Channel Blockers

    2. Cardiac Transplantation/Congestive Heart Failure

    3. Coronary Artery Spasm

  • Joseph Schroers-Martin

    Joseph Schroers-Martin

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.

  • Birgitt Schuele

    Birgitt Schuele

    Associate Professor (Research) of Pathology

    Current Research and Scholarly InterestsThe Schuele lab focuses on neurogenetics, human stem cell modeling, and gene therapy approaches to uncover disease mechanisms and pathways involved in neurodegeneration in Parkinson's, Alzheimer's disease and related disorders.

  • Kevin Schulman

    Kevin Schulman

    Professor of Medicine (Hospital Medicine), by courtesy, of Health Policy and of Operations, Information and Technology at the Graduate School of Business

    BioDr. Schulman is a Professor of Medicine, and, by courtesy, Professor of Operations, Information and Technology at Stanford’s Graduate School of Business. He serves as Interim Division Co-Chief for the Division of Hospital Medicine at Stanford, and as an Associate Chair of the Department of Medicine. He is the Faculty Director of Stanford’s new applied master degree program, the Master of Science in Clinical Informatics Management program. He also serves as Deputy Director of the Clinical Excellence Research Center (CERC) at the Stanford University School of Medicine, and has an appointment in the Department of Health Policy (by courtesy).

    Dr. Schulman is a health economist/health services researcher working at the intersection of business, medicine and technology. With over 500 publications, he has had a broad impact on several areas of health policy (Scopus h-index=81). His research has appeared in the New England Journal of Medicine, the Journal of the American Medical Association, and Health Affairs. He is the editor-in-chief of Health Management, Policy and Innovation (www.HMPI.Org), and Senior Associate Editor of Health Service Research (HSR).

    He is a graduate of Dartmouth College, the New York University School of Medicine, and The Wharton Health Care Management Program. He is an elected member of ASCI and AAP.

  • Liora Schultz

    Liora Schultz

    Clinical Assistant Professor, Pediatrics - Hematology & Oncology

    BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.

  • Neil Schwartz, MD, PhD

    Neil Schwartz, MD, PhD

    Clinical Professor, Neurology & Neurological Sciences
    Clinical Professor (By courtesy), Neurosurgery

    Current Research and Scholarly InterestsMy clinical interests involve inpatient and outpatient care of patients with neurovascular diseases, mostly ischemic and hemorrhagic stroke. I have a particular interest in cervical artery dissection, non-atherosclerotic vasculopathies, and stroke in the young.